Piper Sandler Boosts Kenvue (NYSE:KVUE) Price Target to $27.00

Kenvue (NYSE:KVUE) had its target price boosted by Piper Sandler from $24.00 to $27.00 in a research report report published on Monday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other equities research analysts have also recently issued reports about the company. Barclays lowered their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. UBS Group cut their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Finally, Citigroup cut their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $23.08.

Kenvue Price Performance

Kenvue stock opened at $23.22 on Monday. The firm has a market capitalization of $44.52 billion, a PE ratio of 43.81, a price-to-earnings-growth ratio of 2.62 and a beta of 1.45. Kenvue has a 12-month low of $17.67 and a 12-month high of $24.46. The firm has a 50-day moving average price of $21.36 and a 200-day moving average price of $22.23. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities research analysts forecast that Kenvue will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.53%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio is presently 154.72%.

Institutional Trading of Kenvue

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Heck Capital Advisors LLC purchased a new position in shares of Kenvue during the 4th quarter valued at about $316,000. B. Riley Wealth Advisors Inc. grew its holdings in Kenvue by 18.1% during the fourth quarter. B. Riley Wealth Advisors Inc. now owns 32,455 shares of the company’s stock worth $693,000 after acquiring an additional 4,974 shares during the period. Pullen Investment Management LLC grew its holdings in Kenvue by 46.7% during the fourth quarter. Pullen Investment Management LLC now owns 69,907 shares of the company’s stock worth $1,493,000 after acquiring an additional 22,250 shares during the period. Mackenzie Financial Corp raised its position in Kenvue by 12.8% during the fourth quarter. Mackenzie Financial Corp now owns 444,128 shares of the company’s stock valued at $9,482,000 after acquiring an additional 50,279 shares in the last quarter. Finally, Forum Financial Management LP lifted its holdings in Kenvue by 29.2% in the fourth quarter. Forum Financial Management LP now owns 22,917 shares of the company’s stock valued at $489,000 after acquiring an additional 5,174 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.